NCT06760260View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Human Derived anti-CI135 CAR-T Injection

Autologous genetically modified anti-CI135 CAR transduced T cells

Trial Locations (1)

215000

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY